Results 81 to 90 of about 820 (140)

Transitioning from emicizumab prophylaxis to valoctocogene roxaparvovec gene therapy: A simulation study for individuals with severe haemophilia A [PDF]

Introduction: Valoctocogene roxaparvovec, a gene therapy evaluated in the phase 3 GENEr8-1 trial, supports endogenous factor VIII (FVIII) production to prevent bleeding in people with severe haemophilia A.
Newman, Vanessa, Agarwal, Suresh, Miesbach, Wolfgang, Henshaw, Josh, Hermans, Cedric, Peyvandi, Flora, Sidonio, Robert, Osmond, Dane, Pipe, Steven   +8 more
core   +1 more source

Standard curves required for emicizumab quantification.

, 2022
Typical standard curves resulted from different emicizumab concentrations in (A) manual and (B) automated format. Data were collected for manual configuration in triplicate and for automated configuration in duplicate showed as the means ± s.d. (TIF)
Johannes Oldenburg (138185), Jens Müller (263387), Bernd Pötzsch (615446), Nasim Shahidi Hamedani (13046936)   +3 more
core   +1 more source

Thrombin generation to evaluate the complex hemostatic balance of hemophilia A plasma containing direct oral anticoagulant and supplemented by factor VIII

Research and Practice in Thrombosis and Haemostasis
Background: The incidence of cardiovascular diseases is increasing in persons with hemophilia A (HA). Therefore, anticoagulant therapy based on direct oral anticoagulants (DOACs) may be needed, despite the bleeding risk.
Sylvain Lamoine, Vincent Jury, Virginie Fourneyron, Jonathan Douxfils, Dorian Teissandier, Laurie Talon, Thomas Sinegre, Aurélien Lebreton   +7 more
doaj   +1 more source

Cost-Effectiveness and Budget Impact of Emicizumab Prophylaxis in Haemophilia A Patients with Inhibitors

, 2020
Recent evidence demonstrated that weekly prophylaxis with subcutaneous bispecific antibody (emicizumab) has shown higher efficacy in adolescent and adults patients affected by haemophilia A (HA) with inhibitor, compared with patients treated on demand or
Cortesi P. A., Creazzola S. S., Trifiro G., Mantovani L. G., Castaman G., Improta G., Mazzaglia G., Molinari A. C.   +7 more
core   +1 more source

A Unique Comparison of Tooth Extraction Before and After Emicizumab Prophylaxis in a Patient With Haemophilia A and Inhibitors

Case Reports in Dentistry
Haemophilia A is an inherited X-linked bleeding disorder caused by Factor VIII deficiency; approximately 30% of the patients with haemophilia A develop inhibitors against Factor VIII.
Miki Zaizen, Takahiro Yagyuu, Sachiko Yata, Hiroshi Nakamura, Mitsuhiko Imada, Nobuhiro Yamakawa   +5 more
doaj   +1 more source

Laboratory coagulation tests and emicizumab treatment A United Kingdom Haemophilia Centre Doctors' Organisation guideline.

, 2019
INTRODUCTION The factor VIII mimetic emicizumab (Hemlibra, Hoffman-la Roche, Basel, Switzerland) has a novel mode of action that affects the laboratory monitoring of patients receiving this treatment.
Burgess, Clive, Jenkins, P Vincent, Pratima Chowdary, Will Lester, Kitchen, Steve, Elaine Gray, P. Vincent Jenkins, Bowyer, Annette, Paul Murphy, Clive Burgess, Murphy, Paul, Steve Kitchen, Platton, Sean, Chowdary, Pratima, Annette Bowyer, Riddell, Anne, Lester, Will, Gray, Elaine, Sean Platton, Anne Riddell   +19 more
core   +1 more source

Emicizumab in two patients with acquired haemophilia A – case report

Patients with acquired haemophilia A (PwAHA) can present with severe bleeding and may require lengthy treatment with bypassing agents and immunosuppression. We present two cases of the implementation of emicizumab in PwAHA.
Zhao Milly, Ciolek Alana, Kartika Thomas, Snead Jessica, DeSancho Maria T, Witenko Corey   +5 more
core   +1 more source

Emicizumab for preventing intracranial hemorrhage in infants with severe hemophilia A: a cost-effectiveness analysis

Blood Advances
: Intracranial hemorrhage (ICH) and resulting neurologic disability are severe complications for a subset of infants with severe hemophilia A (HA). Although prophylactic factor replacement reduces bleeding risk, it is typically delayed until after age 1 ...
Samira Glaeser-Khan, Satoko Ito, Manraj Sra, Rhys Richmond, Robert D. Bona, Harlan M. Krumholz, Stacy E. Croteau, Adam Cuker, George Goshua   +8 more
doaj   +1 more source

Concomitant Use of rFVIIa and Emicizumab in People with Hemophilia A with Inhibitors: Current Perspectives and Emerging Clinical Evidence

Therapeutics and Clinical Risk Management, 2020
Silvia Linari, Giancarlo Castaman Department of Oncology, Center for Bleeding Disorders and Coagulation, Careggi University Hospital, Florence, ItalyCorrespondence: Giancarlo CastamanDepartment of Oncology, Center for Bleeding Disorders and Coagulation ...
Linari S, Castaman G
doaj  

Emicizumab prophylaxis in a preterm infant with severe hemophilia A: a case report on the feasibility of early use

Research and Practice in Thrombosis and Haemostasis
Background: Emicizumab provides effective prophylaxis for hemophilia A (HA), but evidence for preterm and very low-birth-weight infants remains limited. Key Clinical Question: Can emicizumab be safely initiated shortly after birth in a preterm, low-birth-
Eman Hassan, Charles Percy, Amna Ahmed, Gillian Lowe, Will Lester, Neil V. Morgan, Jayashree Motwani   +6 more
doaj   +1 more source